| Outcome Measures: |
Primary: Observed maximum plasma concentration (Cmax), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Apparent total body clearance (CL/F), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Non-renal clearance of drug from plasma (CLNR/F), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Apparent volume of distribution based on the terminal phase (Vz/F), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Terminal elimination half-life (t½λz), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 14|Renal clearance of drug from plasma (CLR), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 4|Amount excreted (Ae), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 4|Percentage of dose excreted unchanged in urine (fe), To assess the PK of a single oral dose of AZD4144 in participants with severe renal impairment and ESKD compared with healthy control participants., From Day 1 to Day 4 | Secondary: Number of Treatment Emergent Adverse Events (TEAEs), To evaluate the safety and tolerability of AZD4144 single dose in participants with severe renal impairment, ESKD, and their healthy controls., From Day 1 to Follow-up (Day 14/28)
|
